Application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/ or treating lung inflammation

A technique for dipyridamole and lung inflammation, which is applied in the direction of drug combinations, medical preparations containing active ingredients, antipyretics, etc., can solve the problems of limited research, reduce inflammatory infiltration, reduce fibroblast proliferation and Collagen accumulation, effect of improving respiratory function

Active Publication Date: 2020-07-10
SUN YAT SEN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Phosphodiesterase (PDE) is a specific hydrolase of cAMP and cGMP, and its inhibitor can effectively increase the concentration of cAMP/cGMP and is used in the treatment of various diseases, but it is currently used as a new target drug for anti-

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/ or treating lung inflammation
  • Application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/ or treating lung inflammation
  • Application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of medicine for preventing and/ or treating lung inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Effect of dipyridamole on transformation of HLF-1 cells into myofibroblasts induced by TGF-β

[0047](1) Experimental materials: HLF-1 (human embryonic lung fibroblasts), purchased from the Cell Bank of the Chinese Academy of Sciences; DMEM medium (Gibco, USA); fetal bovine serum (BI, Israel); TGF-β (Proteintech, USA); Pyridamole (2,2',2",2"'-[(4,8-dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)secondary nitrogen] tetra Ethanol, Beide, China); PMSF (Beyond, China); RIPA (Beyond, China); BCA (thermo Fisher Scientific, USA); FN primary antibody (abcam, UK); α-SMA primary antibody (abcam, UK); GAPDH primary antibody (abcam, UK); HRP-goat anti-mouse IgG (BOSTER, China).

[0048] (2) Experimental method: HFL-1 cells were divided into 5×10 5 / mL inoculated in a cell culture dish and cultured overnight to allow the cells to adhere to the wall. The cells were divided into blank control group, model group, and drug administration group. Except for the blank group, ...

Embodiment 2

[0050] Example 2 Effect of dipyridamole on TGF-β-induced fibroblast transformation of NIH / 3T3 cells

[0051] (1) Experimental materials: NIH / 3T3 (mouse embryonic fibroblasts), purchased from the Cell Bank of the Chinese Academy of Sciences; DMEM medium (Gibco, USA); fetal bovine serum (BI, Israel); TGF-β (Proteintech, USA); Pyridamole (2,2',2",2"'-[(4,8-dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)secondary nitrogen] tetra Ethanol, Biide); PMSF (Beyond); RIPA (Beyond); BCA (thermo Fisher Scientific, USA); FN primary antibody (UK abcam); α-SMA primary antibody (UK abcam); GAPDH primary antibody (UK abcam ); HRP-goat anti-mouse IgG (China BOSTER).

[0052] (2) Experimental method: NIH / 3T3 cells were treated with 5×10 5 / mL inoculated in a cell culture dish and cultured overnight to allow the cells to adhere to the wall. The cells were divided into blank control group, model group, and drug administration group. Except for the blank group, 5 μM TGF-β was added, and differen...

Embodiment 3

[0054] Example 3 Effect of dipyridamole on bleomycin-induced pulmonary fibrosis model rats

[0055] (1) Experimental materials: 60 SPF grade SD rats, 6-8 weeks old, weighing 200-250g, male, purchased from the Experimental Animal Center of Sun Yat-sen University (permit number: SYXK (Guangdong) 2016-0112), environment Temperature: 20-25°C, humidity 50-70%, free to eat and drink. Dipyridamole (2,2',2",2"'-[(4,8-dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitro] Tetraethanol, Bi De); Pirfenidone (Shanghai McLean Biochemical Technology Co., Ltd.); Carboxymethylcellulose Sodium CMC-Na (Shanghai Aladdin Biochemical Technology Co., Ltd.); Bleomycin Hydrochloride for Injection (Sea Pfizer Pharmaceuticals Co., Ltd.).

[0056] (2) Experimental method:

[0057] Animal grouping: get 60 male SD rats, randomly divided into: blank group (0.5% CMC-Na), model group (0.5% CMC-Na), pirfenidone administration group (150mg / kg), dipyrim Low-dose administration group of dipyridamole (10 mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and/ or treating lung inflammation. The dipyridamole can inhibit the conversion of fibroblasts into myofibroblasts; meanwhile, the dipyridamole can also improve the respiratory function of a bleomycin-induced pulmonary fibrosis model rat, reduce the inflammatory infiltration of lung tissues and reduce the pathological states such as fibroblast proliferation and collagen accumulation in the lung tissues; and the dipyridamole has relatively high bonding strength with a 3CL enzyme as a pneumonia target triggered by a novel coronavirus in 2019 years, and has relatively high inhibitory activity on the 3CL enzyme of the coronavirus and a Vero E6 cell infected by the coronavirus, indicating that the dipyridamole has the effects of preventing and treating pulmonary fibrosis and pneumonia triggered by the novel coronavirus in 2019 years, and can be preparedinto a pneumonia medicine for application.

Description

technical field [0001] The present invention relates to the fields of pharmaceutical technology and pulmonary disease technology, and more specifically relates to the application of dipyridamole or a pharmaceutically acceptable salt thereof in the preparation of drugs for preventing and / or treating pulmonary inflammation. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) refers to chronic, progressive fibrotic interstitial lung disease of unknown etiology. die. The disease mainly occurs in middle-aged and elderly people over 55 years old, with an incidence rate of about 4.6-16.3 per 100,000 people. my country currently lacks epidemiological statistics of IPF patients, but as a country with a serious aging population, the number of patients is estimated to be more than 500,000 and is increasing year by year. The etiology of IPF is unknown and it is difficult to diagnose. Patients have no symptoms at the early stage. After diagnosis, they are in the middle an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61P11/00A61P29/00A61P31/14
CPCA61K31/519A61P11/00A61P29/00A61P31/14
Inventor 罗海彬吴一诺李哲田怡婧陈健文周倩
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap